This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Asthma

This debilitating condition is caused by narrowing and inflammation of the airways in the lungs; symptoms include recurrent attacks of wheezing, coughing, shortness of breath, and labored breathing. The frequency of asthma has been increasing for all age groups.

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Asthma Study CIGE025A2432

The purpose of this clinical trial is to find out if the drug omalizumab (Xolair®) has beneficial effects on the airways in people who have moderate to severe allergic asthma. Xolair® has been approved in the European Union and by the U.S Food and Drug Administration for the treatment of persistent allergic asthma.
Trial phase: Phase 4
Participation Duration: Participation in the study will last approximately one and a half years. During that time, participants will be asked to visit the study center to receive subcutaneous (under the skin) injections of study medication and assessments.
Protocol Number: CIGE025A2432

Asthma Study CIGE025BUS26

The purpose of this clinical study is to determine how moderate to severe allergic asthma affects the parents and children between the ages of 6 and 11 years old. The study will assess the child’s quality of life, growth, missed days of school, number of medicines required, and number of visits to the doctor’s office required to treat their asthma. The study will also assess how asthma affects their parent’s quality of life and days of work missed due to the child’s asthma. Participating children must be diagnosed with moderate to severe allergic asthma which is not well controlled. This study does not require participating children to take any new medicines or treatments for asthma.
Trial phase: Phase 4
Participation Duration: Participating children and their parent or caregiver will be required to visit the study doctor’s office every 6 months and answer questions at home over the phone monthly, or on paper every 3 months over a 12-24 month period.
Protocol Number: CIGE025BUS26

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Asthma